IJERPH, Vol. 19, Pages 6069: Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
Conclusions: In a real-world setting, in patients with non-active SPMS, the maintaining or switching to the licensed interferon beta 1b did not reduce the risk of reaching confirmed EDSS 7.0. (Source: International Journal of Environmental Research and Public Health)
Source: International Journal of Environmental Research and Public Health - May 17, 2022 Category: Environmental Health Authors: Aurora Zangh ì Emanuele D ’Amico Francesco Patti Carlo Avolio Tags: Brief Report Source Type: research
Recombinant human erythropoietin and interferon- β-1b protect against 3-nitropropionic acid-induced neurotoxicity in rats: possible role of JAK/STAT signaling pathway
In conclusion, the present study demonstrates the neuroprotective potential of rhEPO or IFN-β-1b on 3-NP-induced neurotoxicity in rats. Furthermore, our study suggests that activation of JAK2/STAT 3 or JAK1/STAT3 may contribute to the neuroprotective activity of rhEPO or IFN-β-1b, respectively. We also found that early treatment with rhEPO did not confer any benefits compared with late rhEPO treatment, while early IFN-β-1b showed a marked significant benefit compared with late IFN-β-1b. (Source: Inflammopharmacology)
Source: Inflammopharmacology - March 6, 2022 Category: Drugs & Pharmacology Source Type: research
Viruses, Vol. 14, Pages 444: Interferon- & beta; Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
Viruses, Vol. 14, Pages 444: Interferon-β Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial
Viruses doi: 10.3390/v14020444
Authors:
Heinz-Peter Schultheiss
Claus-Thomas Bock
Ganna Aleshcheva
Christian Baumeier
Wolfgang Poller
Felicitas Escher
Human parvovirus B19 (B19V) is the predominant virus currently detected in endomyocardial biopsies (EMBs). Recent findings indicate that, specifically, transcriptionally active B19V with detectable viral RNA is of prognostic relevance in inflammatory viral cardiomyopathy. We aimed to e...
Source: Viruses - February 21, 2022 Category: Virology Authors: Heinz-Peter Schultheiss Claus-Thomas Bock Ganna Aleshcheva Christian Baumeier Wolfgang Poller Felicitas Escher Tags: Communication Source Type: research
A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector
ConclusionThis study shows that the BETACONNECT device was associated with high adherence to interferon beta-1b therapy in patients with MS. Patients also reported high degrees of satisfaction with the device. Therefore, this may be a viable delivery option to help with adherence and persistence, potentially leading to improved clinical outcomes. (Source: Neurology and Therapy)
Source: Neurology and Therapy - January 22, 2022 Category: Neurology Source Type: research
Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
Introduction
Disease-modifying therapies (DMTs) are the mainstay of treatment for relapsing–remitting multiple sclerosis (RRMS). There is established evidence that DMTs are effective at reducing relapse rate and disease progression in RRMS, but there has been less consideration to the synthesis of MRI and neurocognitive outcomes, which play an increasingly important role in treatment decisions. The aim of this systematic review and network meta-analysis is to examine the relative efficacy, acceptability and tolerability of DMTs for RRMS, using MRI and neurocognitive outcomes.
Methods and analysis
We will search elec...
Source: BMJ Open - November 2, 2021 Category: General Medicine Authors: Lees, S., Dicker, M., Ku, J. E., Chaganti, V., Mew-Sum, M., Wang, N., Smith, A., Oldmeadow, C., Goon, W. L., Bevan, M., Lang, D., Hinwood, M. Tags: Open access, Neurology Source Type: research
Comparing the outcomes of treatment with INF- β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients
CONCLUSION: There was no significant difference between the two groups in terms of shortening the disease time, clinical improvements and other outcomes.PMID:34688151 | PMC:PMC8516800 | DOI:10.1016/j.intimp.2021.108241 (Source: International Immunopharmacology)
Source: International Immunopharmacology - October 23, 2021 Category: Allergy & Immunology Authors: Shahram Seyfi Kayvan Latifi Parviz Amri Male Mahmoud Sadeghi Haddad Zavareh Khadijeh Ezoji Mousa Mohammadnia-Afrozi Source Type: research
The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors
ConclusionIFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - September 30, 2021 Category: Endocrinology Source Type: research
Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study
Despite trends towards the increased age of patients living with multiple sclerosis (MS), little is known about the response of older adults with MS to disease-modifying therapies (DMTs). Thus, a post-hoc analysi... (Source: BMC Neurology)
Source: BMC Neurology - August 23, 2021 Category: Neurology Authors: Francesco Patti, Javier Nicolas Penaherrera, Lorissa Zieger and Eva-Maria Wicklein Tags: Research Source Type: research
Drugs for Multiple Sclerosis
Date: March 22, 2021
Issue #:
1620Summary:
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes. (Source: The Medical Letter)
Source: The Medical Letter - February 9, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Betaseron Cladribine Copaxone dimethyl fumarate diroximel Extavia Fingolimod Gilenya Glatect Glatiramer acetate Glatopa Interferon beta Kesimpta Lemtrada Mavenclad Mayzent mitoxantrone Mul Source Type: research
An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment Strategies.
Authors: Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, Ng LPW, Wong YKE, Pei XM, Li MJW, Wong SCC
Abstract
INTRODUCTION: To date, the transmission of Coronavirus Disease-2019 (COVID-19) is still overwhelming with the fact that numbers of confirmed cases and deaths keep increasing. As of 1 October, 2020, 33,842,281 confirmed cases and 1,010,634 confirmed deaths have been reported to the World Health Organization from 216 countries. Despite the urgent need of effective treatment strategies, there is no specific antiviral treatment for COVID-19 currently and the treatment guidelines for COVID-19 var...
Source: Expert Review of Anti-Infective Therapy - December 12, 2020 Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis
In conclusion, our study indicates that the human gut commensal P. histicola can suppress disease as effectively as commonly used MS drug IFNβ and may provide an alternative treatment option for MS patients. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 11, 2020 Category: Allergy & Immunology Source Type: research
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
(Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - November 9, 2020 Category: Infectious Diseases Authors: Faryal Khamis, Hanan Al Naabi, Adil Al Lawati, Zaiyana Ambusaidi, Mariam Al Sharji, Umkulthum Al Barwani, Nenad Pandak, Zakariya Al Balushi, Maher Al Bahrani, Ibrahim Al-Zakwani Source Type: research
Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue
Publication date: Available online 22 September 2020Source: International Journal of PharmaceuticsAuthor(s): S. Dubey, R. Perozzo, L. Scapozza, Y.N. Kalia (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - September 23, 2020 Category: Drugs & Pharmacology Source Type: research
Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging
Objectives
Gadolinium deposition is widely believed to occur, but questions regarding accumulation pattern and permanence remain. We conducted a retrospective study of intracranial signal changes on monthly triple-dose contrast-enhanced magnetic resonance imaging (MRI) examinations from the previously published Betaseron vs. Copaxone in Multiple Sclerosis With Triple-Dose Gadolinium and 3-Tesla MRI Endpoints Trial (N = 67) to characterize the dynamics of gadolinium deposition in several deep brain nuclei and track persistence versus washout of gadolinium deposition on long-term follow-up (LTFU) examinations (N = 28) obta...
Source: Investigative Radiology - September 9, 2020 Category: Radiology Tags: Original Articles Source Type: research
Emerging pharmacotherapy for COVID-19.
Authors: Lipworth B, Kuo CR, Chan R
Abstract
Broadly speaking, pharmacological treatments for COVID-19 can be divided into those acting on upstream pathways early on in the disease process via suppression of viral replication or by inhibiting cell entry, and those acting on downstream pathways later on via selective attenuation of the adaptive immune cytokine-mediated inflammatory response. The antiviral drug remdesivir has been shown to shorten duration of disease while interferon beta-1b may speed up viral clearance. The results with hydroxychloroquine have thus far been rather disappointing. Trials with...
Source: Journal of the Royal College of Physicians of Edinburgh - June 24, 2020 Category: General Medicine Tags: J R Coll Physicians Edinb Source Type: research
